Novavax, Inc. Share Price Nasdaq
Equities
US6700021040
Biotechnology & Medical Research
Sales 2024 * | 846M 70.53B | Sales 2025 * | 986M 82.29B | Capitalization | 623M 51.98B |
---|---|---|---|---|---|
Net income 2024 * | -112M -9.34B | Net income 2025 * | -90M -7.51B | EV / Sales 2024 * | 0.13 x |
Net cash position 2024 * | 510M 42.58B | Net cash position 2025 * | 482M 40.23B | EV / Sales 2025 * | 0.14 x |
P/E ratio 2024 * |
-6.18
x | P/E ratio 2025 * |
-113
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.34% |
Latest transcript on Novavax, Inc.
Managers | Title | Age | Since |
---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23/23/23 |
John Trizzino
PSD | President | 64 | 10/14/10 |
James Kelly
DFI | Director of Finance/CFO | 58 | 16/21/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 29/22/29 |
Gregg Alton
BRD | Director/Board Member | 58 | 01/20/01 |
David Mott
BRD | Director/Board Member | 58 | 16/20/16 |
1st Jan change | Capi. | |
---|---|---|
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |